EC approves Novartis' Kymriah for follicular lymphoma in adults
The EC has granted approval for Novartis’ CAR-T cell therapy, Kymriah, to treat adults with relapsed or refractory follicular lymphoma.
Stay updated with breaking news from Pharmaceutical Technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The EC has granted approval for Novartis’ CAR-T cell therapy, Kymriah, to treat adults with relapsed or refractory follicular lymphoma.
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest...
Although some countries are moving ahead, the use of CAR-T therapies in the region remains uneven.
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments...
NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest...